FMP
NASDAQ
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
1.35 USD
-0.07 (-5.19%)
Valuation Date:
Apr 22, 2024 4:00 PM
Share Price on Valuation Date
$1.35
Stock Beta
1.56
Shares Outstanding
17334042